key: cord-0689065-u8jgzhp1
authors: Iwasaka, Sho; Shono, Yuji; Tokuda, Kentaro; Nakashima, Kosuke; Yamamoto, Yuzo; Maki, Jun; Nagasaki, Yoji; Shimono, Nobuyuki; Akahoshi, Tomohiko; Taguchi, Tomoaki
title: Clinical improvement in a patient with severe coronavirus disease 2019 after administration of hydroxychloroquine and continuous hemodiafiltlation with nafamostat mesylate
date: 2020-08-06
journal: J Infect Chemother
DOI: 10.1016/j.jiac.2020.08.001
sha: be1083b276450b1dcbcafc860d3b6a2c885b5696
doc_id: 689065
cord_uid: u8jgzhp1

Abstract The number of people infected with severe acute respiratory syndrome coronavirus 2 is increasing globally, and some patients have a fatal clinical course. In light of this situation, the World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19) a pandemic on March 11, 2020. While clinical studies and basic research on a treatment for COVID-19 are ongoing around the world, no treatment has yet been proven to be effective. Several clinical studies have demonstrated the efficacy of chloroquine phosphate and nafamostat mesylate with COVID-19. Here, we report the case of a Japanese patient with COVID-19 with severe respiratory failure who improved following the administration of hydroxychloroquine and continuous hemodiafiltlation with nafamostat mesylate. Hence, hydroxychloroquine with nafamostat mesylate might be a treatment option for severe COVID-19.

the etiological agent for pneumonia of an unknown cause in China [2] . In Japan, there have been 4,768 confirmed cases and 85 deaths as of April 9, 2020 (excluding the cases from the cruise liner outbreak), and of these, 109 patients reportedly required hospitalization in an intensive care unit and/or a ventilator [3] . However, there is no established treatment protocol for this new infectious disease yet, and countries around the world are seeking to develop an effective treatment. The Japanese Association for Infectious Diseases submitted a proposal (first edition) on February 26, 2020, for treating COVID-19 using antiviral medications, with lopinavir/ritonavir (LPV/r) and favipiravir listed as the two drugs for consideration. Here, we have reported the case of a patient who did not respond to treatment with LPV/r and experienced respiratory failure requiring ventilation. Consequently, hydroxychloroquine and continuous hemodiafiltlation with nafamostat mesylate were administered as other treatment approach, resulting in an improvement in the patient's condition.

A 69-year-old Japanese man was admitted to a designated hospital for infectious diseases through a referral by the public health center on February 19, 2020. The patient had no history of recent overseas travel nor any recent contact with anyone who had come from abroad. The only medical history was hypertension and type 2 diabetes, along with a history of smoking (20 cigarettes/day for 30 years, between the ages of 20 and 50 years). The patient had visited a general practitioner after experiencing symptoms of fatigue and a nighttime fever > 38.0 that persisted for a week. Subsequently, a chest X-ray of the patient showed left lung pneumonia, thereby strongly suggesting COVID-19; therefore, he was referred to the public health center. On the same day, the patient's oropharyngeal swab tested positive for SARS-CoV-2 using real time reverse transcriptase polymerase chain reaction (rRT-PCR), and he was subsequently hospitalized in the medical institution designated for infectious diseases. At the time of hospitalization, the patient was overall in a good condition; however, both lungs (predominantly the left) exhibited ground glass opacities on chest computed tomography (CT) (Figure 1 ). Despite the immediate administration of LPV/r (800 mg/day) on the day after hospitalization, the pneumonia spread to the right lung on the second day of hospitalization and resulted in respiratory failure. The oxygen requirement increased up to 7 L/min with a reservoir mask on day 2 and up to 10 L/min on day 3 of admission. Finally, the patient also received mechanical ventilation on day 3. On the same day, the patient was transported to our hospital to receive J o u r n a l P r e -p r o o f extracorporeal membrane oxygenation (ECMO) as swiftly as possible in an isolated negative pressure room.

Although the patient was sedated during transport, he retained clear consciousness prior to intubation. The patient's body temperature was 39.5 ; blood pressure, 144/56 mmHg; pulse rate, 77 beats per minute; and spontaneous respiratory rate, 20/min. The ventilator was set to synchronized intermittent mechanical ventilation mode, with inspired oxygen fraction (FiO2), 0.7; positive end-expiratory pressure (PEEP), 12 cmH 2 O; and pressure support (PS), 10 cmH 2 O. The arterial blood gas test revealed that the arterial partial pressure of oxygen (PaO 2 ) was 82.3 mmHg, arterial partial pressure of carbon dioxide (PaCO 2 ) was 43.1 mmHg, and the PaO 2 / FiO 2 (P/F) ratio was 117 ( Figure 2 ).

Although ECMO was first considered when the patient was transferred, after interdepartmental discussion, ECMO was not initiated as the case did not meet the recommended indications of the Extracorporeal Life Support Organization guidelines [4] .

We began treatment initially with ventilation in accordance with the lung-protective ventilation strategies for acute respiratory distress syndrome (ARDS) [5] . Although LPV/r had been administered for 3 days, it proved to be ineffective. Therefore, we started the patient on the antimalarial medication, hydroxychloroquine, at a dose of 400 mg once a day (the same dosage as is prescribed for systemic lupus erythematosus [SLE]). The CT performed on the second day of hospitalization ( Figure 3 ) showed extensive consolidation of the right lung and ground glass opacities spread over the left lung. The respiratory rate increased to more than 30 breaths/min, indicating overventilation, and the tidal volume was over 8 mL/kg. Therefore, we began the administration of a muscle relaxant (rocuronium) on the same day to lower the tidal volume and reduce the respiratory rate. To address the progressive renal insufficiency, we also began renal replacement therapy using continuous hemodiafiltration (CHDF) with nafamostat mesylate as an anticoagulant [0.2~0.4 mg/kg/hr].

As shown in Figure 2 , the patient began to show some improvement in oxygenation starting from day 3 of hospitalization in our hospital, and on day 4, the P/F ratio improved to surpass the >200 threshold. In addition, chest CT showed improvement in the right lobe pneumonia ( Figure 4 ). On the same day, we discontinued the administration of the muscle relaxant. As an increase in bilirubin starting from day 5 was observed, we discontinued the administration of LPV/r considering the side effects. Respiratory status and imaging results 

In this case report, we have described the case of a critically ill patient with COVID-19 who was administered both of hydroxychloroquine and nafamostat mesylate after his condition continued to worsen despite early administration of LPV/r. After two days of hydroxychloroquine administration, the patient's severe pneumonia condition began to improve, suggesting the potential of hydroxychloroquine with nafamostat mesylate as a possible treatment in patients with COVID-19.

In a recently published randomized controlled trial, LPV/r treatment did not demonstrate any benefit in patients with severe COVID-19 infection [6] . In a post hoc analysis of the trial, clinical recovery and reduced mortality were observed in the subgroup of patients who were treated within 12 days after the onset of symptoms. In our case, although LPV/r treatment was administered early (7 days after onset), it proved to be ineffective.

While the antimalarial drug chloroquine phosphate is recommended in the treatment guidelines for the novel coronavirus according to the National Health Commission of the People's Republic of China [7] at that time, chloroquine phosphate is not currently manufactured in Japan. However, hydroxychloroquine, which has the same pharmacokinetic profile as chloroquine phosphate in addition to reduced toxicity, is already approved in Japan and various other nations for treatment of SLE. Treatment with chloroquine phosphate resulted in the improvement of pneumonia symptoms in over 100 patients, along with significant improvement in clinical measures such as a higher viral clearance rate and a shorter subjective symptom period [8] . In addition, in vitro studies have J o u r n a l P r e -p r o o f demonstrated that the efficacy of hydroxychloroquine was comparable to that of chloroquine phosphate [9, 10] .

Chloroquine impairs the replication of several viruses by increasing the endosomal pH and inhibiting glycosylation [11] . Hydroxychloroquine with azithromycin was also reported to be effective in early viral clearance in an open-label non-randomized trial, although we should be careful of QT prolongation when both of them are administered simultaneously [12] .

Therefore, several clinical studies have been performed to confirm whether chloroquine or hydroxychloroquine is effective. Now most studies concluded hydroxychloroquine is not useful in mild-to-moderate COVID-19 patients [13, 14] and WHO discontinued hydroxychloroquine treatment trial for COVID-19 because of little or no reduction in the mortality of the hospitalized COVID-19 patients.

This time we started not only hydroxychloroquine but also nafamostat mesylate (0.2~0.4 mg/kg/hr) as an anticoagulant for CHDF. Nafamostat mesylate, protease inhibitor, can inhibit the fusion of SARS-CoV-2 to cell membranes by preventing viral protease activity at small blood concentration [15] . Thus nafamostat mesylate was also reported as candidate drugs for COVID-19 and some case series show nafamostat mesylate might be effective [16] .

Doi et al. reported the case series of combination therapy of nafamostat mesylate and favipiravir for severe COVID-19 patients [17] . This report showed the possibility of combination therapy with nafamostat mesylate for severe COVID-19 patients. For that reason, combination therapy of hydroxychloroquine and nafamostat mesylate might affect our patient's improvement.

In addition, COVID-19 also occurs multiorgan coagulopathy what is called disseminated intravascular coagulation (DIC) [18] and nafamostat mesylate is used for DIC in Japan. D-dimer of our patient increased up to 32.6 μg/mL and anticoagulant treatment reported to decrease mortality in severe COVID-19 patients with coagulopathy [19] . So, nafamostat mesylate may also affect the clinical course by improving DIC.

Chloroquine is known to have an immunomodulatory effect via Toll-like receptor signaling pathways, which stimulate the activation of various inflammatory cytokines and T cell receptors in the downstream cascade [20] . In addition, they also demonstrated the hyperactivation of CD4 and CD8 T cells using flow cytometry of the peripheral blood, which implied a high cytotoxic cell response [21] . Therefore, regulating the cytokine release syndrome is critical in patients with severe COVID-19, and some immunomodulatory drugs, such as tocilizumab and steroids, have been investigated for their role as potential therapeutic agents [22] . Hydroxychloroquine immunomodulatory effect may be benefit for COVID-19 patients with severe condition.

Although the mortality rates for COVID-19 have varied widely in different geographic locations, recent report have suggested the mortality rate to be approximately 1.4% [23] .

However, the mortality rate in patients aged > 80 years is as high as 14% in China [24] , and the 28-day mortality rate for severe cases requiring ICU and ventilation is as high as 61.5% [23] . As such, COVID-19 has a high mortality rate for specific demographics. Our case report focuses on the possibility that hydroxychloroquine with nafamostat mesylate might aid in the recovery of patients with severe COVID-19 in a clinical setting. However, our findings derived from a single case cannot be generalized; therefore, further case studies and clinical trials on combination treatment with nafamostat mesylate for COVID-19 are needed.

The authors declare no conflicts of interest in association with the present study.

No funding was obtained from external sources of this study.

Informed consent was obtained from the patient for publication of this case report.

All authors meet the ICMJE authorship criteria. SI managed and wrote the case report. SY and KT contributed to patient management and writing the case report. KN The fever went down from 2 day of admission. The P/F ratio increased day by day up to 300 on day 7 of admission. White blood cell count increased after day 8 and body temperature elevated again after day 9. Gram staining of endotracheal aspirates reveal several morphotypes and neutrophils, but few pathogens cultured. Ventilator-associated pneumonia considered as the cause of the patient's fever. 

World Health Organization. Coronavirus disease (COVID-2019) situation reports

World Health Organization. Pneumonia of unknown case -China

Coronavirus disease 2019 (COVID-19) situation within and outside the country

An Official American Thoracic Society/European Society of Intensive Care Medicine/Society of Critical Care Medicine Clinical Practice Guideline: Mechanical Ventilation in Adult Patients With Acute Respiratory Distress Syndrome. Am J Respir and Crit Care Med

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

Notice on Issuance of the Sixth Edition of the Guidance for COVID-19: Prevention, Control, Diagnosis, and Management

Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discovery

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Effects of chloroquine on viral infections: an old drug against today's diseases?

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int Antimicrob Agents

Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial

Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19

Nafamostat mesylate blocks activation of SARS-CoV-2: New treatment option for COVID-19

Three Cases of Treatment With Nafamostat in Elderly Patients With COVID-19 Pneumonia Who Need Oxygen Therapy

Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series

Autopsy Findings and Venous Thromboembolism in Patients With COVID-19

Anticoagulant Treatment Is Associated With Decreased Mortality in Severe Coronavirus Disease 2019 Patients With Coagulopathy

New insights into mechanisms of therapeutic effects of antimalarial agents in SLE

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Why tocilizumab could be an effective treatment for severe COVID-19?

Clinical Course and Outcomes of Critically Ill Patients With SARS-CoV-2 Pneumonia in Wuhan